Moderna (MRNA) Stock Trades Above Fair Value After Its 479% Run

Moderna stock has delivered a very large 1 year gain, yet the valuation checks still point to an expensive profile rather than a clear bargain. For investors looking at Moderna today, the key issue is how to weigh that sharp share price move against a low value score and a market view that treats the stock as overvalued on multiples.

• Over the past 12 months Moderna has returned about 479%, which sets a high bar for any further upside based purely on improving fundamentals.
• Recent approvals for updated COVID 19 and mRNA flu vaccines can support expectations for future revenue, while the move to issue US$2.6b of convertible notes highlights ongoing funding needs and potential dilution risk for existing shareholders.
• Across the broader checks Moderna screens as expensive rather than cheap, with its low value score of 0 out of 6 indicating that none of these tests flag the stock as a clear bargain.

The issue now is whether Moderna's recent gains already reflect most of the good news that investors are currently pricing in.

Capitalize on Moderna’s sharp move by scanning a curated list of other health and biotech stocks with 37 healthcare AI stocks.

Is Moderna Getting Expensive on Sales?

P/S is often a cleaner way to look at Moderna because the company is still reporting free cash flow losses and P/E does not yet give a stable signal. On this measure, the stock trades at a P/S of about 26.1x, which is roughly double the broader biotech industry average of 13.2x and about three times the peer group average of 8.6x.

The fair P/S ratio from the model sits much lower at around 4.2x. Because this gap is very wide, that figure is better read as a warning that the framework is heavily penalising Moderna for its recent losses and perceived risk rather than a precise target multiple. Despite the approvals for updated COVID 19 and mRNA flu vaccines, the current price still implies a rich valuation relative to both sector norms and this tailored benchmark.

On the preferred P/S multiple, Moderna stock currently screens as clearly overvalued versus its industry and modelled fair ratio.

See what the numbers say about this price — find out in our valuation breakdown.

The Moderna Narrative: What Would Justify Today's Price?

For Moderna, Simply Wall St Narratives pick up where the valuation puzzle leaves off. They spell out which assumptions about future growth, margins and earnings would need to hold for Moderna's stock to be worth materially more or less than today's price, and they sit on Simply Wall St's Community page. Each narrative sets out fair value as a thesis about the business that you can revisit over time, rather than as a one off snapshot.

Community views on Moderna are sharply split, with one camp leaning into the oncology and vaccine optionality while the other questions how much is already priced in.

Bull case: 14% undervalued

"Relentless progress in individualized cancer vaccines, expanding into both adjuvant and metastatic settings, positions Moderna as a future leader in high-value, personalized medicine markets..."

Read the full Bull Case to see why Moderna could be undervalued

Bear case: 229% overvalued

"Sustained decline in COVID-19 vaccine revenues and continued seasonality in the respiratory vaccine portfolio expose Moderna to ongoing revenue volatility..."

Read the full Bear Case to see why Moderna could be overvalued

Do you think there's more to the story for Moderna? Head over to our Community to see what others are saying!

The Bottom Line

For Moderna, the market multiples point to an overvalued stock that already embeds optimistic expectations around the vaccine franchise and broader pipeline. The wide gap between current P/S and both industry levels and the tailored fair ratio suggests that investors are paying a premium for execution and regulatory success that still need to be proved out. From here, the key question is whether Moderna can translate its mRNA platform into durable, less seasonal revenue and margin progress that justifies that premium rather than leaves the stock exposed to a reset in expectations.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com